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Abstract 
 
Introduction 
Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little 
therapeutic progress in the last decade. Novel treatment strategies beyond the established 
standard of care with temozolomide-based radiotherapy are urgently needed. 
Areas covered 
We reviewed the literature on glioblastoma with a focus on phase III trials for 
pharmacotherapies and/or innovative concepts until December 2015.  
Expert opinion 
In the last decade, phase III trials on novel compounds largely failed to introduce efficacious 
pharmacotherapies beyond temozolomide in glioblastoma. So far, inhibition of angiogenesis 
by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as 
alternative dosing schedules of temozolomide did not prolong survival, neither at primary 
diagnosis nor at recurrent disease.  
Promising strategies of pharmacotherapy currently under evaluation represent targeting 
epidermal growth factor receptor (EGFR) with biomarker-stratified patient populations and 
immunotherapeutic concepts including checkpoint inhibition and vaccination. The clinical 
role of the medical device delivering “tumor-treating fields” in newly diagnosed glioblastoma 
which prolonged overall survival in a phase III study has remained controversial. After failure 
of several phase III trials with previously promising agents, improvement of concepts and 
novel compounds are urgently needed to expand the still limited therapeutic options for the 
treatment of glioblastoma. 
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Article highlights  
• For patients with newly diagnosed glioblastoma, the standard of care remains 
temozolomide-based radiochemotherapy. 
• Phase III data on bevacizumab, cilengitide, and alternative dosing schedules for 
temozolomide did not show a survival benefit in newly diagnosed glioblastoma  
• For elderly patients with a methylated MGMT promoter, temozolomide alone is 
probably superior to radiotherapy alone 
• In recurrent disease, no widely accepted standard of care exists. Alkylating 
chemotherapy either as a rechallenge with temozolomide or nitrosoureas (e.g. CCNU), 
and bevacizumab are currently used. The combination of bevacizumab with CCNU is 
not superior for OS to single agent activity of CCNU. 
• Phase III data emerging in the next years will define the role of novel 
immunotherapeutic concepts including checkpoint inhibition and vaccination  
  
 4 
 
1. Introduction  
Glioblastoma, the most common malignant primary brain tumor, has an incidence of 3.2 per 
100,000 with predominance in males according to the Central Brain Tumor Registry of the 
United States (CBTRUS, 2008-2012) [1]. The prognosis for patients with glioblastoma has 
remained poor despite multimodal therapy. Median overall survival (OS) in a population-
based study in the US after the introduction of the standard of care consisting of surgery plus 
temozolomide (TMZ)-based radiochemotherapy in 2005 was 9.7 months for the time frame of 
2005-2008 [2]. In the Canton of Zurich, Switzerland, median OS in patients diagnosed 
between 2005 and 2009 was 11.1 months [3]. Poor prognostic factors include low 
performance status, high age, less than gross total resection, and among molecular markers an 
unmethylated promoter of the DNA repair gene O6-methylguanine-DNA methyltransferase 
(MGMT) as well as wildtype isocitrate dehydrogenase (IDH)-1/2 status [4]. 
During the course of the disease, despite intense initial treatment, tumor recurrence almost 
inevitably occurs. For recurrent disease, no widely accepted standard of care exists. 
Nitrosoureas, TMZ rechallenge or bevacizumab are among the currently used medical options 
for the treatment of recurrent glioblastoma [5-7]. 
Main challenges in developing efficacious pharmacotherapies for glioblastoma include high 
genetic heterogeneity within the tumor and between different patients, rapid development of 
drug resistance and poor distribution of most drugs within the brain [8, 9].  
In this review, we summarize the literature on glioblastoma until December 2015 focussing 
on phase III trials for pharmacotherapies or innovative concepts or compounds currently used 
in the disease. Table 1 gives an overview on the data on completed phase III trials in newly 
diagnosed glioblastoma since 2005. 
 
2. Alkylating chemotherapy 
 
 5 
 
2.1. Temozolomide and the standard of care in newly diagnosed glioblastoma 
TMZ, an imidazotetrazinone prodrug, is characterized by 100% bioavailability in plasma after 
oral intake and proven penetration into the cerebrospinal fluid with about 20% of the area 
under the curve (AUC) of that reached in plasma [10]. Its active metabolite, 5-(3-methyl 
triazen-1-yl)imidazole-4-carboxamide, mediates the cytotoxic effect by methylation of the O6 
position of guanine with additional alkylation at the N7 position [10, 11]. 
The landmark trial in the treatment of glioblastoma represents the phase III trial of the 
European Organisation for Research and Treatment of Cancer (EORTC)/National Cancer 
Institute of Canada Clinical Trials Group (NCIC-CTG) establishing the current standard of 
care and leading to approval of TMZ in newly diagnosed disease [12]. The addition of TMZ 
during and after radiotherapy resulted in prolonged median OS of 14.6 months compared to 
radiotherapy alone (12.1 months). An updated analysis after a median follow-up of more than 
5 years confirmed the efficacy of TMZ showing an OS fraction at 2 years of 27.2%, and 9.8% 
at 5 years in the TMZ arm, versus 10.9% at 2 years and 1.9% at 5 years with radiotherapy 
alone [13]. The administration schedule of the drug in this trial consisted of concomitant TMZ 
during radiotherapy (75 mg/m2 daily) and up to six cycles of adjuvant TMZ (150-200 mg/m2 
for 5 days every 28 days). Toxicity of the drug was mainly hematologic (16% grade 3/4 
events) [12]. The survival benefit in the TMZ group was mainly restricted to patients with a 
methylated MGMT promoter in the tumor with an OS of 21.7 months versus 15.3 months in 
patients without methylated MGMT promoter establishing the role of MGMT as a predictive 
biomarker in glioblastoma [14].  
To improve the efficacy of TMZ and to overcome resistance to TMZ, alternative 
administration schedules, especially with dose intensification have been evaluated in clinical 
trials. One large randomized phase III trial compared the standard schedule of adjuvant TMZ 
(150-200 mg/m2 for 5 days every 28 days) with a dose-dense schedule (TMZ 75-100 mg/m2 
for 21 days every 28 days) in newly diagnosed glioblastoma. No difference in overall survival 
 6 
 
but increased hematologic toxicity was observed. MGMT promoter methylation did not 
predict benefit from intensified TMZ compared to the standard schedule in this trial but was 
associated with prolonged OS independent of treatment [15]. For years, it has remained 
controversial whether extending TMZ beyond the six cycles of the standard schedule would 
improve outcome. A pooled analysis of 4 randomized clinical trials (EORTC/NCIC 26981-
CE.3; EORTC26071-CENTRIC; EMD-CORE; RTOG 0525-Intergroup) did not show a 
benefit for OS if TMZ was extended beyond 6 cycles, including patients with tumors with 
MGMT promoter methylation [16] 
More recently, it was demonstrated by two randomized trials that in elderly patients, e.g. older 
than 60-65 years, TMZ monotherapy in patients with glioblastoma with a methylated MGMT 
promoter was superior to radiotherapy alone having been the standard of care in this patient 
population for decades [17-19]. Based on these data, current guidelines were changed towards 
a biomarker-driven decision-making in elderly patients with newly diagnosed glioblastoma: 
For patients with glioblastomas with an unmethylated MGMT promoter or unknown 
methylation status, hypofractionated radiotherapy alone remains the standard of care while in 
patients with tumors with a methylated MGMT promoter, TMZ without or with radiotherapy 
should be preferred [7]. Whether combined chemoradiotherapy in the elderly patient 
population is superior to radiotherapy alone is currently under evaluation in a randomized 
phase III trial of the NCIC-CTG and EORTC (NCT00482677) [20].  Regarding the radiation 
schedule, a phase III trial with 98 elderly and/or frail patients with low Karnofsky 
performance status (50-70%) demonstrated that a one-week course with 25 Gy in five daily 
fractions was not inferior to standard three-week radiotherapy (total of 40 Gy) [21]. Yet, no 
effort of correlation with molecular markers was made in this study, and quality of life data 
were inconclusive. 
In recurrent glioblastoma, TMZ had been already used prior to its approval in newly 
diagnosed disease based on the data of 2 phase II trials, one single arm study and one 
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randomized trial showing superiority to procarbazine [22, 23]. After establishment of the 
standard of care with TMZ in the newly diagnosed setting, different regimens of TMZ 
reexposure, especially dose-intensified schedules were evaluated for recurrent disease [24].  
Most trials were small uncontrolled single-arm studies with heterogeneous patient populations 
with a median OS ranging between 5.1 and 11.7 months in TMZ-pretreated patients [25-27]. 
The DIRECTOR trial did not find any difference in OS comparing two dose-intensified 
schedules in patients with recurrent glioblastoma (TMZ 80 mg/m2 for 21 days out of 28 days 
versus TMZ 120 mg/m2 for 7 days out of 14 days) [28]. Yet, DIRECTOR showed that dose-
intensified TMZ provides relevant tumor control only in patients with tumors with MGMT 
promoter methylation. In the absence of convincing data, the overall clinical benefit from 
dose-intensified TMZ regimens compared to the standard schedule remains doubtful. 
 
2.2 Nitrosoureas 
Nitrosoureas are a group of DNA alkylating agents characterized by their high lipid solubility 
and thereby ability to cross the blood-brain-barrier which led to their use in brain tumors for 
decades. Carmustine (BCNU), nimustine (ACNU) and fotemustine are administered 
intravenously while lomustine (CCNU) is given orally. Toxicity, especially bone marrow 
suppression and hepatic toxicity, is more prominent than with TMZ.   
Before the approval of TMZ in newly diagnosed glioblastoma, nitrosoureas were frequently 
combined with radiotherapy in the first-line setting [29]. Following the introduction of TMZ 
in the first-line setting, nitrosoureas have been mainly used at recurrence. 
In the last decade, several randomized clinical trials in recurrent glioblastoma chose 
nitrosoureas, especially CCNU as active comparator for the experimental drug. 
Median OS ranged between 7.1 and 9.8 months [25, 30-32]. None of the novel 
pharmacotherapies proved superiority to nitrosoureas so far, indirectly confirming their 
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activity for recurrent disease. Still, relevant toxicity, especially bone marrow suppression, 
limits the use of nitrosureas in glioblastoma patients.  
Gliadel® wafers are a specific local application mode of BCNU shown to prolong survival in 
recurrent malignant glioma [33] and in newly diagnosed malignant glioma [34]. No survival 
benefit was seen in the latter trial when the analysis was restricted to glioblastoma only. 
Although approved in many countries in the world, the use of Gliadel® wafers has probably 
constantly declined over the last years. 
 
3. Antiangiogenic therapy 
Since glioblastomas are highly vascularized tumors, pharmacotherapies inhibiting 
angiogenesis emerged as a promising therapeutic strategy in the last decade. Main ideas of 
that concept included to starve the tumor by disrupting its vessels, to induce vessel 
“normalization” with improved delivery of chemotherapy and to fight a non-neoplastic target 
with limited intrinsic development of resistance.  
However, all clinical trials in glioblastoma conducted so far failed to prove efficacy of anti-
angiogenic compounds with regard to prolonged OS. 
 
3.1 Bevacizumab alone and combination therapy 
The pharmacological compound inhibiting angiogenesis characterized best in glioblastoma 
and also in other tumors represents bevacizumab, a humanized monoclonal antibody against 
the vascular endothelial growth factor (VEGF). Data on pharmacokinetic and bioavailability 
of the drug especially with regard to target inhibition are limited. Serum levels as well as the 
half-life of the drug in tumor patients are highly variable [35]. Based on the molecular 
structure, no penetration across an intact blood-brain-barrier is expected. However, in 
glioblastoma, a disrupted blood-brain-barrier may lead to an intratumoral delivery of the drug. 
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In clinical trials, dosing varied between 5 and 15 mg/kg every 2 or 3 weeks with the most 
common dose of 10 mg/kg every 2 weeks.   
Typical adverse events associated with bevacizumab include arterial hypertension, 
thromboembolic events, cerebral hemorrhage, impaired wound healing and intestinal 
perforation [36, 37]. 
In newly diagnosed glioblastoma, two large phase III trials (AVAGlio, RTOG 0825) 
evaluating TMZ-based radiochemotherapy with or without bevacizumab failed to prove a 
benefit in OS [36, 37]. In both studies, a composite primary endpoint of OS and progression-
free survival (PFS) was chosen. In contrast to OS, a prolongation of PFS was observed in both 
trials, by 4.4 months (AVAGlio), or by 3.4 months (RTOG 0825), although not reaching 
formal significance in the RTOG trial. The discrepancy between prolongation of PFS but not 
OS remains poorly understood. In part, crossover effects (31% AVAGlio, 48% RTOG 0825) 
may have contributed to this disconnect. In addition, determination of progression by 
radiological response criteria is still a controversial topic in neurooncology and may 
potentially be misleading in antiangiogenic therapies. The respective trials used different 
response criteria (RTOG 0825, Macdonald criteria/ AVAGlio, adapted RANO-criteria 
including independent imaging review). Subgroup analyses were performed in order to 
identify those patients likely to benefit from bevacizumab. In the RTOG 0825 trial, neither the 
MGMT status nor a prespecified 9-gene signature identified differences between the study 
groups [36]. In the biomarker population of the AVAGlio trial, IDH1 wild-type tumors were 
analysed for subtypes according gene expression profiles suggesting a benefit of bevacizumab 
in the proneural subtype in contrast to the mesenchymal or proliferative subtypes [38]. Still, 
this was an exploratory endpoint needing confirmation in a clinical trial with corresponding 
pre-specified patient stratification. 
Several combination approaches have been explored in order to improve the efficacy of 
antiangiogenic drugs, especially of bevacizumab. In newly diagnosed glioblastoma, the 
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Glarius trial evaluated in a multicenter phase II design the combination of bevacizumab and 
irinotecan against standard TMZ-based radiochemotherapy in patients with glioblastoma 
harboring an unmethylated MGMT promoter. PFS (5.9 versus 9.7 months) but not OS (16.6 
versus 17.3 months) was significantly prolonged [39].  
In recurrent glioblastoma, bevacizumab was approved in the US and many other countries but 
not in the European Union based on the results of 2 phase II trials achieving radiographic 
response rates around 30% and PFS-6 rates of 42.6 and 29%, respectively [40, 41]. However, 
the effect of bevacizumab on OS remained uncertain since these trials lacked a study arm 
without the experimental drug. The first clinical trial in recurrent glioblastoma evaluating 
bevacizumab with a bevacizumab-free control arm represents the Belob trial [42]. Since this 
trial was conducted in the Netherlands where bevacizumab is not approved, cross-over effects 
were virtually absent. The trial was designed as a three-arm study comparing bevacizumab 
versus CCNU versus the combination of both drugs. The outcome with a median OS of 12 
months of the combination arm versus 8 months of each of the monotherapy arms suggested a 
comparable activity of single agent bevacizumab and CCNU but importantly a benefit of the 
combination treatment. Based on these results, the design of the EORTC-26101 trial was 
adapted. The trial was initially planned as a phase II study with 4 arms randomizing for 
bevacizumab followed by CCNU, CCNU followed by either bevacizumab or best-
investigator’s choice or the combination of both followed by best-investigator’s choice after 
progression on the first regimen. In the adapted design, the combination of bevacizumab and 
CCNU was tested in phase III randomized fashion versus CCNU as a single agent in patients 
with first recurrence of glioblastoma. The outcome data were presented at the 2015 Society 
for Neuro-Oncology (SNO) Meeting. The primary endpoint, OS, was not significantly 
different between CCNU monotherapy (median OS 8.6 months, n=149 patients) and the 
combination with bevacizumab (9.1 months, n=288 patients, hazard ratio (HR) 0.95). PFS 
was longer in the combination arm (4.2 months, HR 0.49) compared to CCNU alone (1.5 
 11 
 
months). Crossover to bevacizumab in the monotherapy arm occurred in 35.5% while 19% of 
the patients in the combination arm continued bevacizumab after tumor progression [32]. 
Subgroup analyses, especially regarding MGMT promoter methylation and gene expression 
profiling, will be provided with the final report of the study.  
In the past, many clinical trials evaluated other drug combinations to improve the efficacy of 
bevacizumab as a single agent in recurrent glioblastoma. So far, both cytotoxic chemotherapy, 
alternative antiangiogenic agents and targeted therapy failed to show substantial effects 
beyond single agent activity [25]. One compound merits to be mentioned: VB-111, a non-
replicating adenovirus vector with modified murine promoter expressing a proapoptotic 
human Fas-chimera in order to target endothelial cells with potential antiangiogenic effects 
was safe in phase I/II in patients with recurrent glioblastoma [43, 44]. The initial design of the 
phase II trial comprised monotherapy with VB-111 (3x1012 or 1x1013 viral particles every 2 
months) until progression followed by bevacizumab. The protocol was amended to continue 
VB-111 with add-on of bevacizumab upon tumor progression. Overall survival was 15 
months for the group with combination therapy at progression (n=24) versus 8 months for 
bevacizumab alone upon progression (n=22)[45]. Based on these results, a phase III trial 
comparing VB-111 combined with bevacizumab vs. bevacizumab is currently conducted in 
patients with recurrent glioblastoma (NCT02511405).  
A common clinical practice in the use of bevacizumab is to continue the drug beyond 
progression on the drug to avoid potential rebound effects based on little retrospective data 
with high probability of selection bias. The phase II CABARET trial evaluated the outcome of 
patients randomized to continue or stop bevacizumab upon progression on either bevacizumab 
alone or combined with carboplatin in patients with recurrent glioblastoma. No differences in 
PFS or OS were reported [46]. 
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3.2 Other anti-angiogenic agents evaluated in phase III trials: Cediranib, cilengitide, 
enzastaurin 
Beyond bevacizumab several other drugs targeting factors involved in angiogenesis have been 
evaluated for the treatment of newly diagnosed or recurrent glioblastoma. 
Cediranib, a tyrosine kinase inhibitor of VEGF receptor-1,-2,-3, PDGFR and c-kit, showed 
similar results regarding PFS rates in phase II as bevacizumab [47].  However, neither as a 
single agent nor in combination with CCNU, it was superior to CCNU monotherapy in a 
phase III trial in recurrent glioblastoma [31]. 
For cilengitide, targeting the integrins αvβ3 and αvβ5 with a putative antiangiogenic effect, 
two phase II trials showed encouraging results with a median OS of 16.1 and 19.7 months in 
newly diagnosed glioblastoma when combined with standard radiochemotherapy and 9.9 
months at recurrence [48-50]. Subgroup analyses suggested a benefit of cilengitide 
specifically in patients with tumors harboring a methylated MGMT promoter [50]. Based on 
these results, a phase III trial (CENTRIC) in patients with newly diagnosed glioblastoma with 
methylated MGMT promoter evaluating cilengitide with and without standard 
radiochemotherapy was conducted. The results were disappointing, showing no difference in 
OS or PFS [51]. A randomized phase II study with 265 patients compared two different 
dosing regimens of cilengitide in combination with standard radiochemotherapy with the 
standard of care alone in patients with newly diagnosed glioblastoma and an unmethylated 
MGMT gene promoter. Since there was no dose-dependent effect on outcome with non-
significant effects of the high dose of cilengitide on PFS and OS, no clear signal for efficacy 
in this patient population was found either [52]. 
Enzastaurin represents another compound potentially inhibiting angiogenic pathways in 
glioblastoma. It is an ATP-competitive inhibitor of protein kinase C-beta involved in 
downstream signaling of VEGF and other pathways. In newly diagnosed glioblastoma, a 
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single arm study for patients without methylation of the MGMT promoter missed its primary 
endpoint with a PFS-6 rate of 53.6% [53]. 
In recurrent glioblastoma, phase II data showed radiographic response rates of 25% but 
limited 6-months PFS of 7% [54]. The subsequent phase III trial for recurrent disease was 
stopped after poor results of an interim analysis without significant differences in PFS and OS 
compared with CCNU [30].   
In conclusion, after failure in phase III, there is no evidence for clinical efficacy in 
glioblastoma of cediranib, cilengitide or enzastaurin.  
 
4. Other targeted therapies 
Agents targeting pathways involved in the pathogenesis of glioblastoma, in part with 
promising effects in other types of cancer, have been extensively evaluated in glioblastoma. A 
detailed discussion of these strategies, recently provided [9], would be beyond the scope of 
this review. Most concepts were not developed beyond phase II because of disappointing 
results.  
An inhibitor of MGMT, O6benzylguanine (O6BG), was tested in a phase III design in 
combination with BCNU plus radiotherapy versus BCNU plus radiotherapy alone with the 
hypothesis to sensitize glioma cells to alkylating chemotherapy. This trial, conducted in the 
pre-TMZ era, was negative both with lack of OS benefit and additional toxicity in the 
experimental arm [55].  
For patients with IDH1 mutated tumors, small molecule inhibitors of IDH1 are in clinical 
development. Since this mutation is an early event in tumorigenesis and absent in healthy 
tissue, it represents an ideal pharmacological target [56]. To date, small molecule inhibitors 
such as AG-881 and AG-120 are in phase I development (NCT02481154, NCT02073994). 
First results of the phase I study of AG-120 in patients with IDH-mutated solid tumors 
including glioma (NCT02073994) were presented at the AACR-NCI-EORTC International 
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Conference on Molecular Targets and Cancer Therapeutics 2015. The drug was well tolerated 
and 10 of the 20 patients with gliomas showed stable disease including 4 out of 11 patients 
with high-grade glioma [57].  
Epidermal growth factor receptor (EGFR) plays a major role in the pathogenesis of 
glioblastoma and has been tried as a target for therapeutic purposes for years despite several 
negative trials, including tyrosine kinase inhibitors such as erlotinib or gefitinib [58, 59] or 
monoclonal antibodies such as nimotuzumab [60]. However, these trials were not conducted 
in biomarker-selected populations overexpressing the target. Recently, in a phase II trial in 
recurrent glioblastoma evaluating the ErbB family blocker afatinib, a small efficacy signal in 
EGFRvIII-positive tumors versus -negative tumors was seen (median PFS 3.4 versus 1.0 
months) [61]. Currently tested in phase IIb/III is ABT-414, an antibody-drug conjugate 
targeting EGFR in its active conformation. The toxicity profile of the drug as assessed in 
phase I trial includes ocular adverse events such as corneal deposits and keratitis. In this trial, 
5 of 18 patients in the cohort combined with TMZ and 2 of 28 patients in the monotherapy 
cohort had objective response. Importantly, all patients with documented radiographic 
response had EGFR amplification [62]. Therefore, in the subsequent clinical trials, only 
patients with amplified EGFR were included. In patients with newly diagnosed glioblastoma, 
the currently recruiting phase IIb/III trial evaluates the combination of ABT-414 with 
standard radiochemotherapy compared to the standard of care alone (NCT02573324). In 
recurrent gliobastoma, patients are randomized to ABT-414 alone or combined with TMZ and 
to CCNU or TMZ (NCT02343406, EORTC 1410).  
 
5.  Immunotherapeutic concepts 
Currently the most promising field in oncology in general as well in glioblastoma represents 
immunotherapy including vaccination approaches and inhibition of immunosuppressive 
molecules [63]. 
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Vaccination approaches aim at mounting a tumor-specific immune response, e.g. via peptides 
derived from tumor-specific antigens or cell-based approaches. The most popular and best 
characterized peptide-based approach represents the vaccination against the variant III of 
EGFR (EGFRvIII) which is present in about 25% of glioblastomas but absent in normal 
tissue. Rindopepimut is a vaccine comprising of an EGFRvIII-derived peptide conjugated 
to keyhole limpet hemocyanin (KLH) serving as a carrier and is administered intradermally 
with granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvant. A phase II 
trial in patients with newly diagnosed glioblastoma (ACT III), initially planned in a 
randomized but open-label fashion, evaluating the addition of Rindopepimut to standard 
radiochemotherapy versus radiochemotherapy alone, was changed to a one-arm design due to 
high drop-out rates in the control arm. Gross total resection, minimal residual disease ≤1 cm2 
and absence of tumor progression after completion of radiation therapy were required for 
study participation. The safety profile was favorable except for local skin reactions at the 
injection site. PFS at 5.5 months after study entry, the primary endpoint of the trial, was 66%. 
Median overall survival of 21.8 months from study entry was encouraging, although the 
highly selected patient population has to be taken into account. Importantly, anti-EGFRvIII 
antibody titers were increased at least 4-fold in 85% of the patients and EGFRvIII was 
eliminated in 4/6 (67%) tumor samples at recurrence after vaccination [64]. These data 
confirm results from 2 smaller phase II trials assessing rindopepimut in patients with newly 
diagnosed glioblastoma [65, 66]. The recently completed phase III trial (ACT IV, 
NCT01480479) was conducted in a double-blind placebo-controlled fashion including a 
placebo vaccine containing KLH. Recently, a press release of the manufacturer reported that 
the trial was discontinued in March 2016 since the study was unlikely to meet its primary 
endpoint (OS). Median OS of the experimental arm (20.4 months) was similar as in prior 
phase II trials, however, the control arm reached comparable results (21.1 months, HR 
0.99)[67].  
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Although the vaccination is thought to work best when used early in the disease with minimal 
residual tumor, rindopepimut has also been evaluated in recurrent glioblastoma. The Re-ACT 
trial randomized patients to bevacizumab plus control vaccine versus bevacizumab combined 
with rindopepimut. Patients in the rindopepimut arm had higher overall response rates (30% 
vs. 18%), PFS-6 (28% vs. 16%) and prolonged median OS (11.3 vs. 9.3 months, HR=0.57). 
Potent anti-EGFRvIII immune titer generation was associated with prolonged OS [68], which 
might also simply reflect immunological fitness as a prognostic factor.  
Another promising neoantigen suitable for peptide-based vaccination represents mutated 
IDH1 (IDHR132H), a mutation occurring early in tumorigenesis and virtually absent in 
normal tissue. Preclinical models support this concept [69]. The currently recruiting phase I 
trial NOA-16 evaluates safety and immune response to the IDH1 peptide vaccine in patients 
with IDH1-mutated WHO grade III and IV gliomas (NCT02454634). 
Another approach to induce anti-tumor immunity which will be assessed in a phase III trial is 
the compound ICT-107, a vaccine of patient-derived dendritic cells incubated with peptides 
derived from 6 tumor-associated antigens (melanoma-associated antigen 1 (MAGE-1), human 
epidermal growth factor receptor 2 (HER2), absent in melanoma 2 (AIM-2), tyrosinase-
related protein-2 (TRP-2), glycoprotein100 (gp100), and interleukin-13 receptor subunit 
alpha-2 (IL-13Rα2). Phase I data showed good tolerability, immune responses were 
demonstrated in one third of the patients [70]. The subsequent phase II trial randomized ICT-
107 in a 2:1 manner in addition to standard radiochemotherapy in patients with newly 
diagnosed glioblastoma. This study showed a significantly improved PFS in the experimental 
arm [71]. In the subgroup of HLA-A2-positive patients immunologic response was associated 
with a median OS of 23.1 months for responders and 13.7 for non-responders [72]. Based on 
these encouraging results, a multi-center randomized, double-blind phase III trial in HLA-A2-
positive patients with newly diagnosed glioblastoma has been initiated (NCT02546102). 
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Another vaccine based on dendritic cells, DCVax®, is currently evaluated in a phase III trial 
(NCT00045968). The therapeutic priniciple, injecting patient-derived dendritic cells pulsed 
with autologous tumor lysate was safe in a phase I trial [73].  
Beyond vaccination, the currently most promising strategy in cancer immunotherapy 
represents immune checkpoint inhibition. These compounds target inhibitory immune cell 
receptors and their ligands such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), 
the receptor programmed cell death-1 (PD-1) or its ligand PD-L1 aiming at overcoming 
tumor-induced immune tolerance. After the success of the first compound in this field, 
ipilimumab, an antibody to CTLA-4, in metastatic melanoma [74], a plethora of agents has 
entered the clinic in cancer therapy and clinical trials. A phase III trial evaluating nivolumab, 
an antibody targeting PD-1, versus bevacizumab in patients with recurrent glioblastoma has 
recently completed accrual (Checkmate 143, NCT02017717). Within a small safety cohort of 
this trial, the OS rate at 6 months was 70% for patients receiving nivolumab alone. 
Monotherapy of nivolumab was well tolerated while the combination with ipilimumab was 
discontinued at phase I because of limiting toxicity including colitis, cholecystitis, diabetic 
ketoacidosis, and confusion [75]. Nivolumab will also be tested in patients with newly 
diagnosed glioblastoma. A phase III trial for patients with glioblastoma and unmethylated 
MGMT promoter will compare standard TMZ-based radiochemotherapy with radiotherapy 
and nivolumab (Checkmate 498, NCT02617589). A companion trial for patients with MGMT 
promoter-methylated glioblastoma is planned. Similar compounds are under development, 
e.g. pembrolizumab (NCT02337491) or MEDI4736 (NCT02336165) currently evaluated in 
phase II.   
 
6. Gene therapy 
Virus-delivered gene therapies may in part mediate their effects via immunological 
mechanisms, too. A phase III trial evaluated a locally applied adenovirus-mediated gene 
 18 
 
therapy with a prodrug converting enzyme (herpes-simplex-virus thymidine kinase; 
sitimagene ceradenovec) followed by intravenous ganciclovir in patients with newly 
diagnosed resectable glioblastoma in addition to standard radiochemotherapy compared to the 
standard of care alone. The co-primary endpoint of the trial, median time to death or re-
intervention, was prolonged in the experimental group (308 days) relative to the control group 
(268 days), in contrast to OS which was not different in both arms [76]. 
 
7. Tumor treating fields 
Beyond pharmacotherapy, a novel modality of anti-tumor therapy was tested in glioblastoma: 
tumor-treating fields (TTFields/NovoTTF) represents a portable device to be carried by the 
patient for at least 18-20 h per day. The device delivers alternating electric fields of low-
intensity and intermediate frequency supposed to have anti-mitotic effects. A randomized 
phase III trial in newly diagnosed glioblastoma demonstrated prolonged PFS (7.1 versus 4.0 
months) and OS (19.6 versus 16.6 months) for the addition of TTFields (>18h/day) to 
maintenance TMZ [77]. Accrual was stopped early for success after a pre-specified interim 
analysis on 315 patients. The design did not include blinding or placebo-control of the device 
and excluded patients with poor outcome since randomization became effective only after 
completion of radiotherapy and required demonstration of stable disease at that timepoint.  
A randomized phase III trial in recurrent glioblastoma had previously evaluated TTFields 
(>20h/day) versus best physician’s choice of chemotherapy. OS and PFS were not 
significantly different [78]. There were no major limitations regarding toxicity in both trials 
except for mild to moderate skin reactions. The FDA has approved the device both for newly 
diagnosed and recurrent glioblastoma. Since patient acceptance of this treatment is limited at 
present, the future place of TTFields in the treatment of glioblastoma remains to be defined. 
 
7. Conclusion 
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In the last ten years, despite several phase III trials with previously promising compounds and 
concepts, little progress has been made in the treatment of patients with glioblastoma. So far, 
no concept added to standard TMZ-based radiochemotherapy resulted in an additional benefit, 
except for the prolongation of OS in one trial by the application of TTFields. Alkylating 
chemotherapy with TMZ using the standard schedule remains the standard of care in newly 
diagnosed glioblastoma. Yet, clinical trials in the subgroup of elderly patients changed the 
previous standard of care, that is, radiotherapy alone: in case of a methylated MGMT 
promoter, TMZ with or without radiotherapy is probably superior to radiotherapy alone. 
Phase III trials with antiangiogenic agents, such as bevacizumab, cilengitide, cediranib or 
enzastaurin were negative despite promising data in phase II studies.  
At recurrence, TMZ rechallenge, nitrosoureas such as CCNU, or bevacizumab where 
available represent widely accepted therapeutic options. Of note, no compound so far showed 
superiority to CCNU in a phase III trial in recurrent glioblastoma. Targeted agents often 
already failed to give an efficacy signal at phase II stage. Various immunotherapeutic 
concepts recently demonstrated encouraging results in phase I/II trials, efficacy results 
derived from randomized phase III trials will be available in the next 1-2 years.  
 
8. Expert opinion 
Improvement of the still poor prognosis of patients with glioblastoma remains a major 
challenge. Disease heterogeneity and rapid development of resistance limit the activity of 
pharmacological treatment. Despite advances in the understanding of the biology of the 
tumor, strategies in targeting key pathogenic mechanisms such as angiogenesis failed to 
prolong OS. Repeatedly, agents with promising data in phase II trials failed to confirm 
efficacy in randomized phase III trials. Table 2 shows current perspectives and summarizes 
clinical trials that will influence the field in the future. Alkylating chemotherapy with TMZ in 
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newly diagnosed glioblastoma and CCNU in recurrent disease will stay an important part of 
future clinical concepts and active comparators for the design of clinical trials. The clinical 
role of TTFields with positive results as an add-on to standard maintenance TMZ in newly 
diagnosed glioblastoma remains controversial. Key criticisms include the lack of blinding and 
placebo control in the phase III trial, which admittedly would have been a challenge for 
various reasons, and the early closure of the trial.  
The perspectives of antiangiogenic compounds after the disappointing results of the clinical 
trials discussed above are uncertain. The future of bevacizumab, the most promising 
antiangiogenic agent, will depend on whether a subgroup of patients deriving benefit from the 
treatment and rational combination therapies can be defined. The identification of predictive 
biomarkers is the logical consequence of the increased molecular understanding of 
glioblastoma. Yet, beyond MGMT promoter methylation as a predictive biomarker for benefit 
from TMZ, no molecular marker or gene signature for benefit from tumor-specific treatment 
has been identified yet. Future efforts should aim at stratifying patients according pre-
specified molecular subgroups with tailored therapeutic concepts. In line with this, the EGFR-
targeted clinical trials, both the vaccination trial ACT-IV and the trial evaluating ABT-414, 
and clinical trials with IDH1 inhibitors or IDH1-targeted vaccinations are conducted in target-
selected populations. However, the recently reported failure of the randomized vaccination 
trial ACT-IV evaluating rindopepimut, an EGFRvIII-targeted vaccine, is disappointing. 
Although phase II data had been promising, admittedly conducted in highly selected patient 
populations, the expectations in phase III were not met. Probably, using randomized trial 
designs already in phase II trials would help to identify concepts worth to be evaluated in 
phase III. 
Despite the failure of ACT-IV, the currently most promising field in the pharmacological 
treatment of glioblastoma still represents immunotherapy. The success of checkpoint 
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inhibitors targeting CTLA-4, PD-1 or PD-L1 in other cancer entities encourages the currently 
conducted clinical trials with these agents in glioblastoma. Other promising 
immunotherapeutic concepts comprise the dendritic-cell based vaccine ICT-107 planned to be 
evaluated in phase III (NCT02546102) and an IDH1-targeted peptide vaccine in IDH1 
mutated tumors (NCT02454634).   
In conclusion, advances in the biological understanding of the tumor are urgently needed to be 
translated into clinically active compounds to improve the still limited therapeutic options in 
glioblastoma. 
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Table 1: Phase III trials in newly diagnosed glioblastoma published between 2005 and 2015 
Clinical trial/ 
Reference 
Patients Investigative 
concept(s) 
Mechanism 
of action 
Treatment arms, no. of 
patients 
Primary 
endpoint 
mPFS 
(months) 
mOS  
(months) 
Status of the drug/conclusions 
EORTC 
26981/22981/ 
NCIC CE3 
[12] 
18 to  
70 y  
TMZ, standard 
schedule: during RT 
(75 mg/m2/d, 6 cycles 
adjuvant (150-200 
mg/m2 for 5d, q28d) 
Alkylation of 
DNA 
TMZ/RT+TMZ 5/28 
(n=286)  
or  
RT (n=287)  
OS 6.9 
(TMZ/RT+TMZ) 
5.8 
(RT) 
 
14.6 
(TMZ/RT+TMZ) 
12.1 
(RT) 
TMZ approved for newly 
diagnosed glioblastoma, current 
standard of care 
MGMT promoter methylation 
predictive biomarker for benefit 
from TMZ 
RTOG 0525 
[15] 
>18 y TMZ, dose-
intensification in 
adjuvant phase:  
6-12 cycles adjuvant 
(75-100 mg/m2 for 21d, 
q28d)  
Alkylation of 
DNA 
Standard TMZ 5/28 
(n=411)  
or   
Dose-dense TMZ 21/28 
(n=422) 
OS 5.5  (Standard 
TMZ) 
6.7 (Dose-dense 
TMZ) 
16.6 (Standard 
TMZ)  
14.9  Dose-dense 
TMZ) 
TMZ approved for newly 
diagnosed glioblastoma 
 
No benefit of dose-dense 
schedule 
 
SWOG S0001/ 
NCT00017147 
[55] 
>18 y O6BG 120 mg/m2 
+BCNU 40 mg/m2 q6w 
MGMT 
depleting 
agent 
(O6BG), 
alkylation of 
DNA 
(BCNU) 
RT+O6BG 120 
mg/m2+BCNU 40 mg/m2  
(n=90) 
or 
RT+BCNU 200 mg/m2+RT 
(n= 89) 
OS 4 (each arm) 11 (O6BG + 
BCNU) 
10 (BCNU) 
Trial stopped for futility at 
interim analysis 
 
No added benefit of O6BG 
 
NOA-08 [19] >65 y TMZ (100 mg/m2 for 
7d, q14d) 
 
 
Alkylation of 
DNA  
TMZ (n=195)  
or  
RT 30x1.8-2.0 Gy (n=178)  
 
OS 3.3 (TMZ) 
4.7 (RT) 
 
8.6 (TMZ) 
9.6 (RT) 
 
TMZ or RT standard of care in 
patients >65y  
 
MGMT promoter methylation 
predictive biomarker for benefit 
of TMZ 
Nordic [18] >60 y TMZ (150-200 mg/m2 
for 5d, q28d) 
 
RT 10x3.4 Gy 
Alkylation of 
DNA (TMZ) 
TMZ 5/28 (n=93)  
or  
RT 10x3.4 Gy (n=98)  
or  
RT 30x2 Gy (n=100) 
OS Not available 8.3 (TMZ 5/28) 
7.5  
(RT 10x3.4 Gy) 
6.0  
(RT 30x2 Gy) 
TMZ or RT 10x3.4 Gy standard 
of care in patients >70y  
 
MGMT promoter methylation 
predictive biomarker for benefit 
of TMZ 
AVAGlio/ 
[37] 
>18 y BEV (10 mg/kg q2w) 
in addition to 
TMZ/RT+TMZ 
Antibody to 
VEGF 
TMZ/RT+TMZ+BEV  
or  
TMZ/RT+TMZ+Placebo 
OS+PFS  10.6 (BEV) 
or  
6.2 (Placebo) 
16.8 (BEV) 
or  
16.7 (Placebo) 
No approval of BEV for newly 
diagnosed glioblastoma 
 
Improved PFS and maintainance 
of quality of life (BEV)  
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Abbreviations: BEV, bevacizumab, CIL, cilengitide; d, days; mPFS, median progression-free survival; mOS, median overall survival; q, every; RT, radiotherapy; TMZ, 
temozolomide; VEGF, vascular endothelial growth factor; wk, week; y, years 
 
 
 
 
 
RTOG 0825 
[36] 
>18 y BEV (10 mg/kg q2w) 
in addition to 
TMZ/RT+TMZ 
Antibody to 
VEGF 
TMZ/RT+TMZ+BEV  
or  
TMZ/RT+TMZ+Placebo 
OS+PFS  10.7 (BEV) 
or  
7.3 (Placebo) 
15.7 (BEV) 
or  
16.1 (Placebo) 
No approval of BEV for newly 
diagnosed glioblastoma 
 
Worse quality of life (BEV)  
[21] >65 y and/or 
KPS 50-70% 
Short-course RT (5x5  
Gy) 
Radiation RT 5x5 Gy (n=48) 
or  
RT 15x2.67 Gy (n=50) 
OS 4.2 (both arms) 7.9 (5x5 Gy) 
6.4 (5x2.67 Gy) 
Short course RT noninferior to 
RT 5x2.67 Gy in elderly and/or 
patients with KPS 50-70% 
CENTRIC/ 
[51] 
>18 y, 
methylated 
MGMT 
promoter 
 
CIL 2000 mg iv. 
twice/wk in addition to 
TMZ/RT+TMZ 
Inhibitor of 
αvβ3/αvβ5 
integrins 
TMZ/RT+TMZ  
(n=273) 
or 
TMZ/RT+TMZ  
+ CIL (n=272) 
OS 10.7 
(TMZ/RT+TMZ) 
13.1 (CIL+ 
TMZ/RT+TMZ)  
26.3 
(TMZ/RT+TMZ) 
26.3 (CIL+ 
TMZ/RT+TMZ) 
No added benefit of CIL 
Drug development stopped for 
glioblastoma 
OSAG 101-
BSA-05 [60] 
18 to  
70 y 
Nimotuzumab 
400mg/wk for 12 wks, 
then twice/wk in 
addition to 
TMZ/RT+TMZ 
Antibody to 
epidermal 
growth 
factor 
receptor  
TMZ/RT+TMZ  
(n=74) 
or 
TMZ/RT+TMZ  
+ nimotuzumab (n=75) 
12-months 
PFS and PFS 
5.6 
(TMZ/RT+TMZ) 
4.0 
(Nimotuzumab+ 
TMZ/RT+TMZ) 
19.5 
(TMZ/RT+TMZ) 
16.7 
(Nimotuzumab+ 
TMZ/RT+TMZ) 
No added benefit of 
nimotuzumab 
 
ASPECT [76] 18 to  
70 y 
Intraoperative injection 
of sitimagene 
ceradenovec (1x1012 
viral particles) 
followed by ganciclovir 
5 mg/kg iv. 2x/d in 
addition to 
TMZ/RT+TMZ 
Adenovirus-
mediated 
gene therapy 
Experimental arm (n=124) 
or 
TMZ/RT+TMZ  (126) 
 
Time to 
death or re-
intervention 
Not available 16.2 
(Experimental) 
14.8 
(TMZ/RT+TMZ) 
No effect on overall survival of 
sitimagene ceradenovec 
EF-14 [77] >18 y NovoTTF-100A after 
completion of TMZ/RT 
in addition to adjuvant 
TMZ 
Alternating 
electric 
fields 
TMZ/RT+TMZ +NovoTTF 
or 
TMZ/RT+TMZ  
PFS 7.1 
(TMZ/RT+TMZ
+NovoTTF) 
4.2 
(TMZ/RT+TMZ) 
19.4 
(TMZ/RT+TMZ+
NovoTTF) 
16.6 
(TMZ/RT+TMZ) 
Trial closed to accrual after 
interim analysis 
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Table 2: Current perspectives in the treatment of glioblastoma 
 
Immunotherapy 
• EGFRvIII-targeted vaccination (ACT-IV phase III, NCT01480479): discontinued, final results pending 
• Checkpoint inhibition: clinical trials ongoing or results pending: e.g. Nivolumab (phase III, NCT02017717),  
 Pembrolizumab (Phase II, NCT02337491), MEDI4736 (Phase II, NCT02336165) 
• ICT-107 (dendritic cell-based vaccine): phase III (NCT02546102) 
• DCVax (Autologous dendritic cells pulsed with tumor lysate antigen): phase III (NCT00045968) 
• IDH-1 peptide vaccine in patients with IDH-1 mutated tumors (Phase I, NCT02454634, ongoing) 
Alkylating chemotherapy 
• No pharmacotherapy so far showed superiority to either TMZ in newly diagnosed glioblastoma or nitrosoureas in recurrent disease  
Biomarker-driven decision making 
• MGMT promotor methylation predictive for benefit from TMZ and used for decision making in elderly patients 
Targeting amplified EGFR 
• Phase IIb/III trial on ABT-414 in newly diagnosed glioblastoma (NCT02573324): recruiting 
• Phase II trial on ABT-414 in recurrent glioblastoma (NCT02343406): recruiting 
Inhibition of angiogenesis 
• No effect of BEV on OS demonstrated in phase III (AVAGlio, RTOG-0825, EORTC-26101) 
• Identify subgroups of patients deriving benefit of BEV 
• Potentially efficacious combinations:  
 Re-ACT phase II: Rindopepimut+BEV 
 NCT02511405: VB-111+BEV (Recruiting) 
Alternative approaches 
• EF-14 phase III trial (Novo-TTF) 
Abbreviations: BEV, bevacizumab; TMZ, temozolomide 
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Abbreviations 
AIM-2, absent in melanoma 2 
EGFR, epidermal growth factor receptor 
Gp100, glycoprotein100 
HR, hazard ratio 
HER2, human epidermal growth factor receptor 2 
IDH, Isocitrate dehydrogenase 
IL-13Rα2, interleukin-13 receptor subunit alpha-2 
MAGE-1, melanoma-associated antigen 1 
MGMT, O6-methylguanine-DNA methyltransferase  
PFS, progression-free survival 
OS, overall survival 
TMZ, temozolomide 
TRP-2, tyrosinase-related protein-2  
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